Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
To determine safety, tolerability, and preliminary efficacy of escalating doses of SD-101 alone and SD-101 plus ribavirin in subjects with chronic hepatitis C and no prior therapy.
Epistemonikos ID: bad61822ae9d9a34c2cc329299d42686127e8d9b
First added on: Mar 23, 2020